Hong Kong Announced Thursday Lifting of Flight Baan Citing Little Effect’ on COVID
https://abcnews.go.com/Health/wireStory/hong-kong-lifts-flight-ban-citing-effect-covid-86354189?utm_source=dlvr.it&utm_medium=twitter
Keybanc Maintains Overweight on Riskified, Lowers Price Target to $6
Keybanc analyst Josh Beck maintains Riskified (NYSE:RSKD) with a Overweight and lowers the price target from $7 to $6.
B of A Securities Downgrades Kohl’s to Underperform, Lowers Price Target to $26
B of A Securities analyst Lorraine Hutchinson downgrades Kohl's (NYSE:KSS) from Neutral to Underperform and lowers the price target from $50 to $26.
Citigroup Maintains Sell on AMC Entertainment, Lowers Price Target to $5
Citigroup analyst Jason Bazinet maintains AMC Entertainment (NYSE:AMC) with a Sell and lowers the price target from $6 to $5.
Baird Downgrades Aspen Technology to Neutral, Lowers Price Target to $162
Baird analyst Rob Oliver downgrades Aspen Technology (NASDAQ:AZPN) from Outperform to Neutral and lowers the price target from $170 to $162.
Gilat Awarded Follow-On Orders To Expand Defense Force SATCOM Network In An Asian Nation
Gilat Satellite Networks Ltd. (NASDAQ:GILT, TASE: GILT)))), a worldwide leader in satellite networking technology, solutions, and services, announced today it was awarded follow-on orders for the expansion of a defense
Citigroup Maintains Buy on DoorDash, Lowers Price Target to $118
Citigroup analyst Ronald Josey maintains DoorDash (NYSE:DASH) with a Buy and lowers the price target from $138 to $118.
HIVE Blockchain Provides June 2022 Production Update
June 2022 Production Figures
HIVE is pleased to announce its June 2022 production figures and mining capacity:
278.5 BTC Produced
2.17 Exahash of Bitcoin mining capacity at beginning of June
Increased to 2.24
Zynerba Pharmaceuticals Announces Panel Presentation And Poster Presentations At The NFXF International Fragile X Conference
Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced two poster
Enservco Q1 Sales $4.08M Up From $2.39M YoY
Enservco (AMEX:ENSV) reported $4.08 million in sales this quarter. This is a 70.71 percent increase over sales of $2.39 million the same period last year.